-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 4th, Kanghong Pharmaceutical issued an announcement stating that its wholly-owned subsidiary had recently received the "Drug Clinical Trial Approval Notice" for Conbercept ophthalmic injection issued by the State Food and Drug Administration, and agreed to carry out clinical trials
.
It is reported that the product can bind to VEGF in blood vessels and tissues and block the signal transmission that promotes the sprouting and growth of new blood vessels mediated by VEGF
.
Conbercept ophthalmic injection was approved in 2013 for the treatment of wet age-related macular degeneration (nAMD), and in 2017 it was approved for the treatment of visual impairment (pmCNV) secondary to pathological myopia caused by choroidal neovascularization.